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Cyclic AMP treatment of hepatoma cells leads to
increased protein binding at the cyclic AMP response
element (CRE) of the tyrosine aminotransferase (TAT)
gene in vivo, as revealed by genomic footprinting, whereas
no increase is observed at the CRE of the phospho-
enolpyruvate carboxykinase (PEPCK) gene. Several
criteria establish that the 43 kDa CREB protein is
interacting with both of these sites. Two classes of CRE
with different affinity for CREB are described. One class,
including the TATCRE, is characterized by asymmetric
and weak binding sites (CGTCA), whereas the second
class containing symmetrical TGACGTCA sites shows a
much higher binding affinity for CREB. Both classes
show an increase in binding after phosphorylation of
CREB by protein kinase A (PKA). An in vivo
phosphorylation-dependent change in binding of CREB
increases the occupancy of weak binding sites used for
transactivation, such as the TATCRE, while high affinty
sites may have constitutive binding of transcriptionally
active and inactive CREB dimers, as demonstrated by
in vivo footprinting at the PEPCK CRE. Thus, lower
basal level and higher relative stimulation of transcription
by cyclic AMP through low affmiity CREs should result,
allowing finely tuned control of gene activation.
Key words: cAMP response elements/CREB/DNA binding/
in vivo footprinting/PKA protein phosphorylation
Introduction
Cells respond to changes in their environment by transmitting
external signals through several internal pathways, eliciting
immediate alterations by changes in enzyme activities or later
responses by reprogramming gene expression. One well
characterized signal transduction pathway acts through
protein kinase A (PKA). An increase in the level of the
second messenger cyclic AMP (cAMP) activates PKA,
resulting in phosphorylation of numerous protein substrates
(reviewed in Edelman et al., 1987), leading in some cases
to changes in expression of target genes (reviewed in Roesler
et al., 1988; Montminy et al., 1990). The study of genes
whose transcription is cAMP responsive revealed a common
cAMP response element (CRE) TGACGTCA (Deutsch
et al., 1988a,b). A 43 kDa protein termed CREB binds to
this sequence (Montminy and Bilezikjian, 1987) and leads
to increased activation of transcription after phosphorylation
by PKA (Yamamoto et al., 1988; Gonzalez and Montminy,
Oxford University Press
1989). A number of proteins have been identified which are
related to CREB in their DNA binding domain and which
recognize identical or closely related DNA sequences (Hardy
and Shenk, 1988; Hai et al., 1988, 1989; Gaire et al., 1990;
Hurst et al., 1990 and references therein). All appear to be
leucine zipper proteins which bind DNA as dimers
(Landschulz et al., 1988) and CREB has been shown to be
present as a dimer in solution (Dwarki et al., 1990). Many
of the leucine zipper proteins have been shown to
heterodimerize with various other members of their class
(Benbrook and Jones, 1990; Hai and Curran, 1991),
however, CREB is relatively selective in that it has been
reported to heterodimerize only with ATF-1 (Hurst et al.,
1991) and CREM (Foulkes et al., 1991). CREB and CREMT
are the only members of the CREB/ATF family which have
been shown directly to mediate cAMP induction of
transcription (Gonzalez and Montminy, 1989; Hurst et al.,
1991; Foulkes et al., 1992).
The tyrosine aminotransferase (TAT) gene contains a
functional CRE 3.6 kb upstream of the transcription start
site as an essential component of a liver-specific enhancer
(Boshart et al., 1990; Weih et al., 1990). Protein binding
to this site depends on the state of phosphorylation as
revealed by genomic footprinting: increased intracellular
cAMP concentration led to an increase in protein binding
(Weih et al., 1990), and inhibition of PKA by over-
expression of the regulatory subunit RIca results in a virtual
disappearence of this DNA binding activity (Boshart et al.,
1991).
We have focused on purification and characterization of
the cAMP-induced DNA binding protein from rat liver
which interacts with the CRE of the TAT gene (TATCRE)
in vivo. Since PKA was reported not to stimulate binding
of CREB to the somatostatin CRE (Montminy and
Bilezikjian, 1987; Yamamoto et al., 1988), we anticipated
that a different member of the CREB/ATF family would
recognize the TATCRE in a phosphorylation-dependent
manner. However, we show that phosphorylation of CREB
by the catalytic subunit of PKA increases binding to several
CREs, including the TATCRE. In hepatoma cells, genomic
footprinting revealed that binding at the TATCRE, a weak
CREB binding site, increased after cAMP stimulation,
whereas for the PEPCK gene which is also cAMP
responsive, the high-affinity CREB binding site showed no
further increased binding after cAMP stimulation. Hence,
the basal and stimulated PKA activity levels within the cell
are very important in determining the degree to which CRE
enhancers are bound by CREB and activate transcription.
Results
Two separable binding activities interact with the
TATCRE
Genomic footprinting studies showed that binding activity
at the TATCRE in vivo correlates with PKA activity (Weih
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et al., 1990; Boshart et al., 1991). To characterize this
binding activity, rat liver extracts were fractionated into three
specific binding activities, A, B and C (Figure lA), as
characterized earlier in bandshift assays using crude nuclear
extracts of hepatoma cells (Weih et al., 1990). The B and
C complexes are very closely related by all criteria of
analysis and are referred to as BC. Methylation interference
and bandshift analyses have shown that both A and BC
proteins bind to the TATCRE, but not to the mutant version
(MUTCRE), which has three substitutions at nucleotides
contacted by protein in vivo (Weih et al., 1990). The three
MUTCRE sequence changes were also shown to be sufficient
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Fig. 1. Two separable factors interact with the TATCRE. Rat liver
nuclear extracts were applied to DEAE-sepharose and proteins were
eluted with a 50-500 mM KCI gradient. Aliquots of fractions were
assayed for binding activities in bandshift assays with the TATCRE
oligodeoxynucleotide (A). The BC activity elutes at - 100 mM KCI
from DEAE-sepharose (lanes 4-6). The A activity elutes at -200
mM KCI (lanes 7-11). Lane 1 shows the starting material activities.
A non-specific binding protein complex is marked by NS and binds
equally well to the TATCRE, SOMCRE and MUTCRE DNAs (not
shown). In (B) fractions from the DEAE-sepharose, containing
primarily the BC or the A activity, were treated with the catalytic
subunit of protein kinase A (+) prior to the bandshift assays.
:: .
to inactivate the enhancer in vivo (Boshart et al., 1990; Weih
et al., 1990). Since the BC complex was more abundant in
cells following cAMP induction, in contrast to the A complex(Weih et al., 1990), we anticipated that this binding activity
may correspond to the cAMP-inducible binding activity
observed in vivo. The BC activity recognizes both the CRE
of the TAT and somatostatin genes while the protein forming
the A complex recognizes only the TATCRE (data not
shown).
BC binding to the TATCRE can be increased by
treatment with the catalytic subunit of protein
kinase A
We tested directly the effects of the catalytic subunit of PKA
on the bandshift activities, after fractionating rat liver nuclear
extracts using DEAE-sepharose or S-sepharose. We found
that the shifted band due to binding of BC to the TATCRE
was altered in mobility and intensity after PKA treatment,
whereas the A binding activity was not affected by PKA
(Figure 1B). This shows a direct link between PKA and the
BC binding activity, which is not apparent for the A
protein(s). Hence, BC is most likely to be the binding activity
responsible for the cAMP-inducible footprint in vivo. Each
of the two separable activities (A and BC, Figure 1) was
purified independently using native DNA cellulose and
specific TATCRE oligodeoxynucleotide chromatography.
CREB and the BC proteins are both recognized by
antibodies to a short peptide of CREB
In order to define the relationship between the BC activity
from liver and the CREB factor (Yamamoto et al., 1988),
we also purified CREB from rat brain. To determine the
antigenic relatedness ofCREB and the BC protein from liver,
polyclonal antibodies against CREB were generated using
a peptide representing amino acids 137-150 of rat brain
CREB as antigen (Gonzalez et al., 1989). In Western blot
analyses, the anti-CREB antiserum reacted with a single
Fig. 2. Anti-CREB antibodies react with a 43 kDa protein in the BC fraction from liver which comigrates with CREB from brain. In (A) proteins
from liver and brain of rats were included in Western blot analysis using anti-CREB antibodies generated to a short peptide sequence from CREB.
Samples include 150 jig protein from FTO2B extract, 50 jtg of a partially purified heparin-sepharose fraction (HEP) and samples of
oligodeoxynucleotide affinity purified A, BC and brain CREB fractions (- 1, 1 and 0.2 stg protein, respectively). Positions of marker proteins from
Sigma are shown at the left. CREB is 43 kDa relative to egg albumin (45 kDa). In (B) affinity purified BC of liver was preincubated with pre-immune serum (PI) or antiserum (I) to CREB, prior to the addition of labelled DNA in a standard bandshift reaction. The CREB-antibody-DNA
complex is marked by (*). Using concentrated antibodies (ab) (C), separated B and C forms of the BC fraction were completely immunoshifted whenbound to the TATCRE (lanes 1-4). The BC fraction bound to the consensus SOMCRE was immunoshifted (lanes 5-6), as was the purified brain
CREB bound to the SOMCRE (D).
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protein migrating at 43 kDa in both the BC and CREB
fractions (Figure 2A). This protein was also detected as the
most abundant specific immunoreactive protein in nuclear
extract from FT02B cells (a hepatoma cell line that expresses
TAT) and a partially purified BC fraction from liver. The
antibodies did not recognize protein from the purified A
fraction. Therefore, BC and CREB share specific antigenic
determinants corresponding to amino acids 137-150 of
CREB.
In addition, bandshifts performed with purified BC from
liver in the presence of antiserum show a specific
immunocomplex, denoted by *, most likely corresponding
to a BC -antibody -DNA complex, which is not present in
bandshift assays containing the pre-immune serum
(Figure 2B). Hence, the antibodies recognize native BC
protein bound to DNA. To test the relationship between
complexes B and C, two fractions that were almost devoid
of the other form were tested in immuno-bandshift assays
using concentrated anti-CREB antibodies (see Materials and
methods). A complex of slower mobility with proteins
comprising either the B or C complex from liver (showing
relatedness of the two forms; Figure 2C), as well as the
purified CREB from rat brain (Figure 2D) was obtained,
indicating that the proteins each share the CREB epitope.
The shift in mobility by the affinity-purified antibodies
(Figure 2C and D) appears to be quantitatively complete as
DNA binding is not inhibited. These results were observed
with the BC fraction bound to the TATCRE or to the
consensus CRE of the somatostatin gene (SOMCRE). As
also shown in Western blot analysis (Figure 2A), the anti-
CREB antibodies do not recognize the A protein(s) in
immuno-bandshift assays (data not shown). Thus, BC from
liver and CREB may be related or identical, while the A
protein does not appear to be related to CREB.
Phosphorylation of CREB purified from rat brain
increases binding to the TATCRE
To test whether the increased binding seen in partially
purified fractions from liver after PKA treatment is brought
about by CREB homodimers, we tested highly purified
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Fig. 3. CREB binding to the TATCRE is dependent on
phosphorylation. In (A) proteins from the oligodeoxynucleotide affinity
purification of rat brain CREB were analysed by SDS-PAGE and
silver staining. Aliquots of the starting material (lane 1), the flow-
through (lane 2) and the retained protein (lane 3) are shown. The
marker proteins are shown at the left (lane M). Bandshift assays with
PKA- or PP2A-treated brain CREB are shown in (B). Equivalent
amounts of purified CREB were incubated with PKA alone, PP2A
alone, or PP2A followed by PKA in the presence of okadaic acid to
inhibit PP2A activity. All lanes in Figure 3B contain the same amount
of purified CREB protein. Each of the three samples of treated CREB
was mixed with 0.5, 2.5, 5 or 10 fmol (lanes 1-4, 5-8 and 9-12,
respectively) of labelled TATCRE and incubated for 1 h on ice. The
enzyme treatment of CREB is shown at the bottom of the lanes.
kDa band (Figure 3A), for phosphorylation-induced binding
to the TATCRE. We analysed binding activity of brain
CREB which had been treated with either the catalytic
subunit of PKA to fully phosphorylate the PKA site(s), or
with protein phosphatase 2A (PP2A) to remove phosphates.
CREB treated with PP2A showed little binding to the
TATCRE as compared with the PKA-treated sample
(Figure 3B). The bandshift activity after PP2A treatment
could be recovered when the protein was rephosphorylated
by PKA in the presence of okadaic acid, which inhibits
PP2A. Therefore, as for the BC activity from rat liver, it
appears that the phosphorylation state of CREB influences
DNA binding to the TATCRE.
A 43 kDa protein present in the CREB and BC
fractions is the major substrate for the catalytic
subunit of PKA in vitro
The most probable explanation for the increased binding to
the TATCRE with the liver BC and the brain CREB fractions
after incubation with PKA is that phosphorylation of a protein
present in both of those fractions mediates DNA binding.
To identify the substrates for PKA, the purified BC and
CREB fractions were phosphorylated in vitro using purified
catalytic subunit of PKA and [-y-32P]ATP. The reaction
products were resolved by SDS-PAGE and reveal that the
only major substrate for PKA in each of these fractions was
a 43 kDa protein (Figure 4A). This phosphoprotein
comigrates with the immunoreactive protein shown in
Western blot analysis (Figure 2A) and the purified protein
in the silver stained SDS gel (Figure 3A), suggesting that
they are identical. Additional phosphoproteins detected in
the liver fraction were not consistently present in this assay
and may be degradation products of the 43 kDa protein.
When the A fraction was used as substrate for PKA, no
phosphoproteins were seen, confirming that it is not a direct
target of PKA (not shown).
Phosphorylation of Ser133 by PKA increases binding
to the TATCRE
Phosphoamino acid analysis of the major 43 kDa
phosphoprotein confirmed that both BC and CREB were
labelled only at serine residues upon phosphorylation with
PKA in vitro (not shown). To determine the site(s) of
phosphorylation, we performed tryptic digests and two-
dimensional peptide analyses of the 43 kDa phosphoproteins
from the BC and CREB fractions. They each showed the
same single tryptic phosphopeptide, following phos-
phorylation by the catalytic subunit of PKA in vitro, whose
identity was confirmed by mixing experiments including a
synthetic marker peptide predicted from the CREB sequence
(Figure 4B). Thus, a single site (Serl33) on CREB from
rat brain and BC from liver is phosphorylated by PKA in
vitro. An otherwise identical marker peptide containing Ala
in place of Ser at position 133 could not be phosphorylated
by PKA, confirming the phosphorylation site (data not
shown).
To compare the residue(s) modified in vitro and in vivo,
phosphorylation of the 43 kDa protein in response to
forskolin was examined in FT02B hepatoma cells.
Following phosphorylation in vivo, only a 43 kDa
phosphoprotein was immunoprecipitated from soluble
cellular proteins by the CREB antibodies and peptide analysis
was performed. The same tryptic phosphopeptide was





Fig. 4. The major substrate of PKA in the purified BC and brain CREB fractions is a 43 kDa protein, and two-dimensional tryptic peptide mapping
of the 43 kDa phosphoprotein identifies Serl33 as the PKA-dependent phosphorylation site. Aliquots of either brain CREB or liver BC fractions were
phosphorylated by PKA using [-y-32P]ATP and reaction products were run in triplicate on a 10% SDS-polyacrylamide gel (A). The 43 kDa
phosphoprotein from BC or CREB fractions was digested by trypsin following phosphorylation with PKA in vitro. Trypsin digests were subjected to
phosphopeptide mapping as described in Materials and methods. Peptides were resolved in the horizontal dimension by electrophoresis and in the
vertical dimension by ascending chromatography (B). An arrow marks the origin. A single phosphopeptide is observed with BC or CREB,
phosphorylated in vitro by PKA and it migrates at an identical position as the phosphorylated marker peptide when mixed (CREB + Marker
peptide). Phospholabelled CREB was immunoprecipitated from equal amounts of extracts of FTO2B cells which had been incubated for 4 h with
then treated with forskolin (or solvent control) and subjected to phosphopeptide mapping (B). The single phosphopeptide observed migrated
identically with the marker peptide in mixing experiments (not shown). CREB from liver is a multiply modified protein (C). An aliquot of the BC
fraction from liver was labelled using PKA and [-y-32P]ATP, mixed with a 100-fold excess of untreated BC fraction and resolved by two-dimensional
electrophoresis. The resulting gel was further analysed by Western blotting and the immunostained forms are shown in the panel labelled ab. The
autoradiograph of the blotted proteins is shown in the panel labelled 32p. Immunostaining with anti-CREB antibodies reveals five forms migrating at
43 kDa. The 32p signal identifies those proteins which have been labelled in vitro by PKA. The CREB proteins shift by only one charge interval (as
determined by isoelectric focusing gel markers) after PKA phosphorylation and are summarized schematically in the lower half of the figure. The
cathode (+) and anode (-) for the isoelectric focusing gel are noted at the top of the figure.
purified CREB or marker peptide phosphorylated by PKA
in vitro. The amount of phosphate at the Ser133 site increased
after forskolin treatment of the cells (Figure 4B and Boshart
et al., 1991). Therefore, the collective evidence from
bandshift assays, antibody analysis, SDS gel migration, PKA
phosphorylation and phosphopeptide mapping shows that the
BC protein from liver is the same as CREB from brain.
Multiple modified forms of CREB exist in liver
To see whether multiple phosphorylated forms exist in vivo,
we analysed CREB from liver by two-dimensional protein
gel electrophoresis, followed by Western blot analyses. We
found that there are five protein species of Mr 43 000
(labelled 1-5), differing by net charge increments of one
and centred at pl = -5.8, which are recognized by the
CREB antibodies (Figure 4C). After phosphorylation with
PKA of purified CREB from liver, all five species (1-5)
quantitatively moved one charge interval toward the cathode
(+), consistent with increased negative charge from one
added phosphate. This indicates that only one PKA site is
present in CREB, in agreement with the tryptic peptide
analysis (Figure 4B). Since all CREB forms (1-5) are
substrates for the PKA phosphorylation, prior modification
appears not to be required for phosphorylation at Serl33.
Two forms of CREB (a and A) have been identified which
differ only by an alternatively spliced a-exon, encoding 14
amino acids (Yamamoto et al., 1990; Ruppert et al., 1992).
The ca-specific amino acids contribute a net charge of +2,
so CREBaz forms should migrate two charge units toward
the anode (-), relative to the CREBA forms. This was
confirmed using the a and A forms of CREB protein
expressed in Escherichia coli (data not shown). With this
in mind, forms 3-5 correspond to CREBA while forms 1-3
correspond to CREBa (Figure 4C). Hence, CREBA would
comprise 80-90% of the CREB protein found in both liver
and brain (proteins from both sources show identical 2-D
patterns), consistent with mRNA ratios in liver (Ruppert
et al., 1992) and brain (Yamamoto et al., 1990).
Phosphorylation consensus sites for additional protein
kinases are present N-terminal to the PKA site in CREB (Lee
et al., 1990) and are not resolved in tryptic peptide analysis
as the tryptic fragment containing these sites is larger than
100 amino acids. Surprisingly, the migration of the CREB
forms in the 2-D gel analysis (Figure 4C) are not changed
by extensive treatment with several phosphatases, arguing
that these forms differ by something other than phosphates,
or that the phosphates are extremely resistant to these
phosphatases. However, phosphatases PP2A and PP1 are
capable of completely reversing the migration change caused
by PKA treatment in vitro (not shown). These modifications
may include glycosylation as can be predicted from the
protein sequence. In any case PKA phosphorylation at
Serl33 does not require protein modification at other sites.
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In vivo footprinting reveals enhanced binding at the
TATCRE but not at the PEPCK CRE after forskolin
treatment
We have seen previously in hepatoma cells that binding to
the TATCRE was increased by PKA stimulation (Weih
et al., 1990). We wished to extend our analysis to another
CRE that is active in hepatoma cells and therefore analysed
protein binding in vivo at the CRE of the PEPCK gene, with
and without stimulation of PKA by forskolin. The CRE of
the PEPCK gene is well characterized (Quinn et al., 1988)
and is a representative of the symmetric CRE type (see
below). As well, PEPCK gene transcription is induced by
increased intracellular cAMP levels in hepatoma cells
(Wynshaw-Boris et al., 1984; Stewart and Schutz, 1987;
Sasaki and Granner, 1988). As shown in Figure 5, the TAT
and PEPCK CREs clearly show a footprint in FT02B
hepatoma cells, relative to the DMS protection pattern in
the fibrosarcoma cell line XC, which does not express TAT
or PEPCK and does not show a footprint even after forskolin
treatment (not shown). The DMS protection patterns at the
PEPCK CRE in uninduced (un) and forskolin induced
(cAMP) hepatoma cells appear to be identical. This is in
contrast to the increased occupancy at the TATCRE after
forskolin induction (Figure 5A; Weih et al., 1990). We also
examined protein binding at the PEPCK CRE in FT02B
hepatoma cell derivatives (clones # 17 and # 21) which have
a strongly repressed level of PKA activity, resulting from
overexpression of the PKA regulatory subunit RIct (Boshart
et al., 1991). In these cells, the footprint at the PEPCK CRE
and the TATCRE nearly disappears, confirming that binding
to both CREs is sensitive to PKA activity, and correlating
with the strongly reduced expression of the PEPCK and TAT
genes in these cell lines (Boshart et al., 1991).
High and low affinity CREs show increased binding
by CREB after PKA phosphorylation
The observation that binding of CREB to the TATCRE is
enhanced after PKA activation in vivo or in vitro prompted
us to examine other CREs in bandshift assays, particularly
as the PEPCK CRE did not show increased binding in vivo
when hepatoma cells were stimulated with forskolin
(Figure 5). Since the most striking difference between the
TATCRE and consensus CREs such as the somatostatin CRE
is that the former is asymmetric (ctgCGTCA) and the latter
symmetric (TGACGTCA), we analysed additional well
characterized CREs from these two classes (Figure 6). Two
CREs upstream of the urokinase-type plasminogen activator
gene (uPA-A and uPA-B; von der Ahe et al., 1990) and a
CRE from the proenkephalin gene (ENK; Comb et al.,
1988) are in the asymmetric CRE category, while the
somatostatin (SOM; Montminy and Bilezikjian, 1987), ct-
chorionic gonadotropin (oaCG; Delegeane et al., 1987) and
the fibronectin (FIB; Dean et al., 1989) genes have
symmetric CREs. We also designed a mutant with three
nucleotide changes in the symmetric SOMCRE which
changed it to the asymmetric class (SOM 5/8). This
collection of nine sequences was then tested in bandshift
assays with CREBa protein from an E. coli expression clone,
thereby assuring homodimer CREB protein (Figure 6).
Similar results were found using protein encoded by the
CREBA cDNA in either E. coli or baculovirus expression
systems (data not shown). Clearly, a difference in binding
PEPCK CRE
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Fig. 5. The in vivo footprints at the TATCRE and the PEPCK CRE
are regulated by PKA activity. Wild-type FT02B cells and those
overexpressing the Rla regulatory subunit of PKA under the control of
the mouse metallothionein I promoter (clones # 17 and #21; Boshart
et al., 1991) were grown and induced as described in Materials and
methods. The FT02B cell samples were either uninduced (un) or
stimulated with forskolin (cAMP) to activate PKA. Cells were
incubated with DMS and prepared for genomic footprinting as outlined
in Becker et al. (1992). A TAT and PEPCK non-expressing
fibrosarcoma cell line (XC) was included as a control. Altered DMS
reactivity of guanosines is marked with closed squares for
enhancements and open squares for protections, for both strands.
Numbers indicate the positions of base pairs relative to the start site of
transcription. The conserved CRE core is boxed and shows an
identical protection pattern for both genes.
affinity is apparent for the two CRE classes. The asymmetric
CREs are much weaker binding sites relative to the
symmetric sites (Figure 6A). Additionally, when the CREB
protein was treated with PKA in vitro (+), binding to the
asymmetric CREs was increased relative to the PP2A-treated
(-) samples, whereas binding to the symmetric CREs was
unaffected under these conditions (Figure 6A). Increased
binding to the symmetric CREs was only observed when
assayed with sufficient excess DNA fragment (Figure 6B;
four times more DNA fragment than in Figure 6A). Thus,
it appears that there are two types of CRE elements.
Symmetric CREs bind CREB tightly, whereas asymmetric
CREs are relatively weakly bound. Binding to both classes
is increased by phosphorylation of CREB, though as shown
at the PEPCK CRE in hepatoma cells, high affinity sites in
vivo may be already bound by CREB at basal level PKA
activity.
To determine the difference between the symmetric
SOMCRE and asymmetric TATCRE binding affinities for
the CREB protein, as well as the magnitude of
phosphorylation-induced increase in this binding, titration
experiments with CREBa expressed in E. coli were
performed. Using a constant amount of protein and labelled
DNA, increasing amounts of the same unlabelled DNA
fragment were added to the bandshift reactions (Figure 7).
As seen in Figure 6, the increased binding at the symmetric
consensus CRE of the somatostatin gene after PKA treatment
was observed only at higher DNA concentrations (lanes
4-7), where there was a sufficient excess of DNA. CREB
affinity for the TATCRE was measured to be - 10-fold
lower than that for the SOMCRE under our binding
conditions (KdTAT of -20 nM and KdsoM of - 1.5 nM),
and the phosphorylation at Ser133 increased binding to
the CREs by -3-fold. CREB-DNA complexes on the
SOMCRE were also stable at significantly higher KCI
concentrations in bandshift reactions than complexes with
the TATCRE (300 versus 150 mM, data not shown), again
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Fig. 6. Phosphorylation of CREB affects its binding to two sets of CREs. E.coli expressed CREBca was analysed in bandshift assays using the DNA
sequences from two different classes of CREs, asymmetric and symmetric, shown in (C) (left and right columns, respectively). The nucleotide
positions of the CRE relative to the start site of transcription is given at the ends of each sequence. The resulting bandshifts with asymmetric or
symmetric CREs are shown in panel A and were performed with CREB protein pre-incubated with either PP2A (- lanes) or PKA (+ lanes). Each
lane contains 50 fmol of double-stranded oligodeoxynucleotide probe. The CREB-DNA complexes are indicated on the left. The bandshift assays
with the symmetric CREs (SOM, caCG, FIB and PEPCK), shown in Figure 6B, contain four times more DNA probe (200 fmol per reaction; 20
nM) and also show phosphorylation-enhanced binding for the high affinity CREs.
reflecting inherent binding affinity differences at
physiological ionic strength.
Discussion
CREB binding is affected by PKA activity
In accordance with increased in vivo protein binding at the
TATCRE after activation of PKA by forskolin, we show
here that treatment of a purified liver nuclear protein with
PKA in vitro results in increased binding to the TATCRE
sequence. This protein is shown by direct comparison to be
the 43 kDa CREB protein, using antibody recognition in
Western blot analyses, bandshift experiments and by
mapping of the site phosphorylated by PKA in vivo and in
vitro. Specific DNA binding is reduced by PP2A and can
be restored by PKA treatment in vitro. The magnitude of
the increased binding of CREB to the TATCRE in response
to phosphorylation at Serl33 is comparable to the increased
footprint in vivo. Furthermore, the in vivo occupancy of the
TATCRE exactly reflects the PKA activity state (repressed,
uninduced, induced) and the transcription rate of the TAT
gene in hepatoma cells (Weih et al., 1990; Boshart et al.,
1991). In uninduced FT02B hepatoma cells, CREB is
already bound to the high affinity CRE of the PEPCK gene
and this binding is not increased further after forskolin
treatment, even though PEPCK transcription is increased.
When basal PKA activity is strongly repressed by
overexpressing its regulatory subunit RIat, the PEPCK CRE
binds less protein, presumably resulting from lower affinity
of the non-phosphorylated form of CREB. This corresponds
to a strongly reduced expression of PEPCK under these
conditions (Boshart et al., 1991) and confirms that binding
to both the TATCRE and the PEPCK CRE are responsive
to in vivo PKA activity. One possible explanation is that when
both subunits of CREB dimers are in the dephosphorylated
form at Serl33, as in the PKA repressed cells, no binding
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Fig. 7. Competition binding assays for CREB with the TATCRE and
SOMCRE. To determrine the relative affinities of CREB for the
TATCRE and SOMCRE, bandshift reactions with increasing amounts
of DNA fragment were performed. A constant amount of labelled
DNA fragment was added in each lane (20 fmol) while unlabelled
DNA (same sequence as the probe) was increased from 0 to 640 fmol
as competitor (for lanes 1-7: 0x, I x, 2x, 4x, 8x, 16x, 32x,
molar excess unlabelled DNA, respectively). A constant amount of
E.coli expressed CREBce protein (- 10 fmol), treated with either
PP2A or PKA, was present in each reaction.
in vivo is observed at the endogenous CREs. At the basal,
uninduced level ofPKA activity, a mixture ofCREB dimers
with one or two Serl33 phosphates leads to full occupancy
of the PEPCK CRE, but at an intermediate transcription
level. Upon PKA stimulation, CREB dimers with both
Ser133 phosphates may show greater transactivation function
through the PEPCK CRE, as it remains fully bound. CREBoe
homodimer protein from an expression clone in E.coli
showed inducible binding to CREs. We have also made
similar observations with CREBA expressed in E.coli,
baculovirus, or rabbit reticulocyte lysate systems (not
shown). In addition, in vitro translated ATF-1, a closely
related protein to CREB, can heterodimerize with CREB,
but in contrast to the heterodimers, binding of ATF-l
homodimers was unaffected by PKA (W.Schmid,
-4
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unpublished data). This agrees with poor transcriptional
transactivation by ATF-i in response to cAMP, as
demonstrated by Hurst et al. (1991). Recently, one CREM
isoform (CREMT) which is highly expressed in testis and
is also very similar to CREB has been described. CREMr
can act as a PKA-dependent transcription activator, in
contrast to the other CREM forms which act as repressors
(Foulkes et al., 1992), but it is unclear whether DNA binding
is affected by PKA treatment. It is possible that a
CREB-CREM repressor form is replaced by a PKA
phosphorylated CREB homodimer upon forskolin treatment
of FTO2B cells, explaining the constitutive footprint at the
PEPCK CRE. However, this would not explain the absence
of a footprint in PKA repressed cells and we have not
observed significant CREM protein in FTO2B or liver.
Phosphorylation of a number of other transcription factors
has been shown to lead to changes in the overall transcription
profile, resulting in some cases from altering DNA binding
affinity. The c-Myb protein may activate a different set of
genes after its phosphorylation by CKII (Luscher et al.,
1990). Phosphorylation of transcription factors can thereby
link signal transduction to differential gene expression (for
review see Bohmann, 1990).
Two classes of CREs exist which differ by CREB
affinity
Most characterized CRE sequences fall into two categories.
The palindromic TGACGTCA CRE is composed of two of
the functional CGTCA units which overlap in opposite DNA
strands to form a symmetrical CRE. The asymmetric CREs
contain only one CGTCA unit. The presence of two CGTCA
units, not the presence of a palindromic sequence per se
(Fink et al., 1988), stabilizes binding of the homodimeric
CREB complex. The scissors-grip model for leucine zipper
DNA binding proteins (Vinson et al., 1989) would predict
that for asymmetrical CREs, only one of the two subunits
of a CREB homodimer has an optimal CGTCA binding site,
resulting in a lower net affinity, as demonstrated in bandshift
assays above (Figures 6 and 7) and in Southwestern
experiments using symmetric or asymmetric CRE probes
(M.Nichols and B.Luckow, unpublished data). For low
affinity, asymmetric CREs, phosphorylation-dependent
transcriptional activation results in part from increased CREB
binding to the CRE. This is also consistent with the model
that phosphorylation at Serl33 leads to further transactivation
through protein -protein interactions with the RNA
polymerase II complex (Lee et al., 1990; Yamamoto et al.,
1990). These observations imply that two distinct properties,
DNA binding and transcription transactivation, can be
modulated by one and the same phosphorylation at Serl33
of CREB.
What is the physiological significance of this differential
binding? Phosphorylation at Ser133 is required for
transcriptional activation by CREB (Gonzalez and
Montminy, 1989). Since high affinity CREs bind CREB
more efficiently than low affinity sites, more of the
phosphorylated (active) CREB will be bound to symmetric
CREs, exhibiting a higher basal level expression for those
genes. On the other hand, high affinity sites should also bind
more non- or hemi-phosphorylated (inactive) CREB dimers
than low affinity sites, leading to potential inhibition or
blocking of those sites. Consequently, an increase in CREB
phosphorylation after cAMP stimulation should result in a
higher fold induction in transcription of genes with a low
affinity CRE for two reasons: unphosphorylated
(transcriptionally inactive) CREB dimers are less likely to
bind to asymmetric sites and the basal level expression is
lower initially. Concordantly, CREB has been shown to bind
the AP-1/CRE site of the c-jun gene and block transactivation
by AP- 1 through DNA binding at that site (Lamph et al.,
1990). However, if the PKA activity in the cells was
increased by cotransfecting the catalytic subunit gene,
phosphorylation of CREB led to increased reporter gene
expression alone, or in addition to AP-1 transactivation by
TPA. A CREB mutant which contained Alal33 only acted
as a repressor which was not relieved by increased PKA
activity, and a CREB mutant which does not bind DNA
neither represses nor transactivates (Lamph et al., 1990).
Hence, CREB can be a repressor or activator at the same
DNA site, depending on its state of phosphorylation. CREB
may bind high affinity symmetric CREs in an analogous way.
For the PEPCK CRE in FTO2B hepatoma cells,
phosphorylation of CREB by PKA, resulting in increased
transcription, must either occur directly on CREB dimers
already bound to the CRE or be dependent on the turnover
rate of inactive CREB dimers bound at the CRE. The
TATCRE is free to bind CREB dimers after they are
phosphorylated by PKA, increasing the occupancy at the
TATCRE as seen in genomic footprinting assays, and hence
the transactivation. This also predicts that asymmetric CREs
show a lower basal level transcription but a higher fold of
induction by cAMP than the symmetric CREs. Consistent
with that, the TAT gene does show lower basal level and
higher fold induction by cAMP than the PEPCK gene in
newborn mouse livers (Ruppert et al., 1990) and in FTO2B
hepatoma cells (Stewart and Schiitz, 1987; Boshart et al.,
1991), cells in which both genes are normally expressed.
The dual role of CREB in activation or repression also
explains the requirement for cotransfection of the PKA
catalytic subunit gene with the CREB gene to see
transactivation at CREs (Gonzalez and Montminy, 1989;
Lamph et al., 1990).
Do conformational changes of CREB due to
phosphorylation increase binding to the TATCRE? The
phosphate at Ser133 most likely does not contact the DNA
binding site directly but results in a different conformation
of CREB. This is suggested experimentally by the altered
mobility of the PKA-treated CREB bandshifts in native
PAGE (e.g. Figures 6 and 7) and is consistent with previous
proposals (Yamamoto et al., 1990; Gonzalez et al., 1991).
This conformational change facilitates binding to the CREs.
Thus, as cAMP levels increase and PKA is activated above
basal level, the low affinity CREs are more often in the
bound state, broadening the overall cAMP response.
Similarly, phosphorylation of c-Myb by CKII selectively
inhibits binding to the weaker Myb binding sites whereas
binding to the stronger Myb elements is relatively unaffected
(Liischer et al., 1990). Therefore the set of target genes for
activation by CREB and c-Myb may change after increased
phosphorylation. For other transcription factors, it has been
shown that protein conformation can influence and be
influenced by DNA binding. The yeast protein PRTF has
alternative conformations when bound to enhancer sequences
of ce-specific versus a-specific yeast genes, differing in
transactivation (Tan and Richmond, 1990). The AP-1 factor
changes conformation upon DNA binding (Patel et al.,
1990), as does the GCN4 DNA binding domain (Weiss
et al., 1990). Similarly, phosphorylation of CREB may lead
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to conformational changes which increase DNA binding as
well as subsequent transcription activation of target genes.
CREB exhibits multiple forms in vivo
Two-dimensional electrophoresis of CREB purified from
liver indicates that CREB exists in multiple forms in vivo
(Figure 4C). The fact that all forms of CREB (forms 3-5
for CREBA, forms 1-3 for CREBa) can be a substrate for
PKA implies that phosphorylation by PKA is independent
of previous modifications. However, the nature of some
modifications may include glycosylation, as PP2A and PPl
phosphatases were unable even partially to change the 2-D
pattern. It is unknown whether Ser133 phosphorylation is
a prerequisite for phosphorylation at other sites.
Phosphorylation at sites other than Ser 133 may occur as the
result of activation of other signal transduction pathways
which alter the activity of CREB toward possible subsets
of binding sites, leading to transactivation or transrepression.
Sites on CREB for protein kinase C (Yamamoto et al., 1988)
and CKII have been shown to be phosphorylated in vitro
by those enzymes, though with no clear functional
consequence, and still other phosphorylation sites have been
proposed (Lee et al., 1990). Ca2+/calmodulin-dependent
kinases I and H (CaM kinase), mediating calcium and
depolarization signals in neuronal PC12 cells, phosphorylate
CREB in vitro at Serl33, correlating to increased
transcription of c-fos through a CRE (Dash et al., 1991;
Sheng et al., 1991). Other CREB/ATF proteins may also
modulate CRE enhancer function by binding CREs
independently of CREB or as heterodimers with CREB.
Clearly, the DNA binding and transactivation functions of
CREB could be controlled by many converging pathways,
resulting in a complex balance of transcriptional control.
Materials and methods
Purification of TATCRE binding activities from rat liver
After preparation of nuclei from rat liver (Gorski et al., 1986), nuclear extract
was prepared as described by Dignam et al. (1983). A 10-60% ammonium
sulfate fractionation of the extract was used as starting material for
chromatography. The extract was desalted using a G25 column or dialysis
into a buffer containing 10 mM HEPES (pH 7.9), 1 mM DTT, 1 mM
EDTA, 5 mM MgCl2, 10% glycerol and 50 mM KCI and
chromatographed on DEAE-sepharose (Pharmacia). The BC activity (CREB)
eluted from DEAE-sepharose at - 100mM KCI while the A activity eluted
at - 200mM KCI. The BC and A activities were pooled separately, dialysed
against 10 mM HEPES (pH 7.9), 5 mM DTT, 10 mM EDTA, 5 mM
MgCI2, 20% glycerol and 200 mM KCI and chromatographed on DNA
cellulose (Pharmacia) to enrich for DNA binding proteins. Finally, a DNA
affinity column made with oligodeoxynucleotides containing the TATCRE
sequence (CTGCGTCA) was employed to isolate the CRE binding proteins
(Kadonaga and Tjian, 1986). Ten jig/ml calf thymus DNA was added to
the starting material prior to chromatography on the TATCRE DNA column
to reduce non-specific protein binding.
Preparation of CREB from rat brain or overexpressing cDNA
clones
Extracts from rat brain were fractionated on DEAE-sepharose, DNA
cellulose and then on an oligodeoxynucleotide affinity matrix containing
the palindromic somatostatin CRE, as described by Zhu et al. (1989). The
preparation of the 43 kDa CREB protein was used in comparative analyses
with the liver factor(s) which bind to TATCRE.
Full length cDNA clones of CREBa and CREBA from mouse (Ruppert
et al., 1992) were cloned into either E. coli expression vectors (Rosenberg
et al., 1987) or baculovirus (Invitrogen). Baculovirus expressed CREB was
purified by the same procedure as CREB from rat brain, while isolation
of E.coli expressed CREBa and CREBA was performed as described in
Muller et al. (1989). The E.coli expressed protein used in bandshift assays
was a 30-60% ammonium sulfate fraction from the crude extract, followed
by dialysis.
Bandshift assays
Oligodeoxynucleotides were synthesized which included the TATCRE
sequence, CTGCGTCA, centred within 26 nucleotides of wild-type TAT
sequence. This DNA was cloned (Weih et al., 1990) and then used for
bandshift assays, or synthetic double-stranded oligodeoxynucleotides were
used. A mutant oligodeoxynucleotide (MUTCRE), with three base changes
in the core sequence (CTGtaTgA) at the three contact sites known from
in vivo footprinting (Weih et al., 1990), was used as negative control.
Differential competition and binding affinities between the wild-type and
mutant DNAs were the criteria for potentially interesting DNA-protein
complexes. The SOMCRE oligodeoxynucleotide contains the palindrome
TGACGTCA from the -50 bp region of the somatostatin gene. Bandshift
oligodeoxynucleotides were labelled at the 3'-ends with Klenow polymerase
and gel-purified. The conditions for the bandshift reactions are described
in Weih et al. (1990). In experiments with purified or expressed proteins,
no non-specific DNA was added to the reactions and 0.5 mg/ml of carrier
protein was included (BSA or insulin). The incubation of DNA fragment
with protein factor was for 30 min on ice, unless otherwise stated. Reactions
to determine binding affinity were performed at 24°C with 130 mM KCI,
10 mM DTT, 5 mM HEPES (pH 7.9), 0.5 mg/ml BSA for 60 min, before
native PAGE in 8% gels containing 0.3 xTBE. Immune or pre-immune
antisera were incubated with protein for 15 min before addition of labelled
DNA, in those reactions where immuno-bandshifts were analysed.
Protein kinase A (PKA catalytic subunit) and protein
phosphatase 2A (PP2A) assays
Protein kinase A assays were performed by treating purified liver, brain,
or recombinant factors with 0.1 tg (30 ng) of purified catalytic subunit of
protein kinase A provided by U.Walter and S.Lohmann (Wurzburg). The
reaction buffer contained 10 mM HEPES (pH 7.9), 10 mM MgCl2, 1 mM
ATP, 10 mM DTT, 10% glycerol and 20-100 mM KCI. Incubation was
at 30°C for 20-60 min. Phosphorylation reactions intended to generate
radioactive substrate proteins contained 0.2 uM [-y-32P]ATP (no unlabelled
ATP added). Purified PP2A from rabbit muscle was provided by
B.Hemmings (Basel) and used in a buffer containing 10 mM HEPES (pH
7.9), 5 mM MgCI2, 3 mM MnCI2, 1 mM EDTA, 10 mM DTT, 10%
glycerol and 20 mM KCI. Incubation was at 30°C for I h, a sufficient time
to remove 95% of the in vitro incorporated radioactive phosphate on protein
(data not shown). For samples which were treated with PKA after PP2A,
okadaic acid was added to 100 nM to inhibit the PP2A activity, prior to
addition of PKA and ATP.
Western analysis
Rabbit polyclonal antibodies recognizing CREB were generated using a
synthesized peptide from the published CREB sequence (amino acids
137-150, Gonzalez et al., 1989) as antigen. We further affinity-purified
the antibodies using the synthetic CREB oligopeptide bound to a column,
as described in Harlow and Lane (1988), to increase the specific antibody
titre. Proteins were resolved on SDS gels, electroblotted onto nitrocellulose
membranes and treated in Westem analysis as described by Harlow and
Lane (1988). Signals arise from the activity of alkaline phosphatase, linked
via Extravidin to biotinylated goat anti-rabbit IgG (Sigma).
Two-dimensional protein gel analysis
These experiments were performed as outlined in Ausubel et al. (1988).
Samples were loaded on the isoelectric focusing gels with gradients set up
by 3 parts pH 3-10 ampholyte and 5 parts pH 4-6.5 ampholyte
(Pharmacia), and the IEF marker used was 30 kDa carbonic anhydrase (pi
4.8-6.7; Pharmacia). Second dimension SDS-PAGE was followed by
electroblotting on to nitrocellulose membranes and Western analysis (see
above).
Phosphopeptide mapping analysis
To map the sites of phosphorylation of the liver and brain CREB proteins,
the purified factors were labelled in vitro with the catalytic subunit of PKA
as described above and then isolated from 10% SDS gels. The only major
and consistently labelled band migrated at 43 kDa (see Figure 4A).
Phosphoamino acid analysis was performed by digesting the labelled protein
gel piece in 6 N HCI at 1 10°C for 5 h and then running high voltage
electrophoresis (including phosphoserine, phosphothreonine, phosphotyrosine
and Pi as markers) to resolve the products. Tryptic peptide analysis was
performed as described in Boshart et al. (1991). A marker peptide was
synthesized with the sequences of amino acids 124-136 of CREB (Gonzalez
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et al., 1989). Phosphorylation by PKA and trypsin digestion of the 13 amino
acid peptide generated the tryptic marker phosphopeptide, containing
[32P]Ser133 of CREB.
Tryptic mapping of in vivo labelled protein was performed similarly (see
Boshart et al., 1991, for more details). Briefly, FTO2B cells were labelled
with I mCi 32p; in P,-free medium for 4 h and then treated with forskolin(10 AM), or 0.1 % ethanol for 10 min. Equal amounts of protein in extracts
from the 32P-labelled cells were incubated with the anti-CREB antibodies
described above to normalize the subsequent phosphopeptide mapping. CREB
was immunoprecipitated, using sheep anti-rabbit IgG coupled to paramagnetic
beads (Dynal, Hamburg) and purified on a 10% SDS gel.
Genomic footprinting and probe synthesis
Cell lines were cultured as described earlier (Boshart et al., 1991). FTO2B
cells were either induced with 20 yiM forskolin for 30 min or treated with
0.1 % ethanol as solvent control. The cell lines clones # 17 and # 21 were
treated for 18 h in serum-free medium with 25 AM ZnC12 to induce the
mouse metallothionein I promoter driving a mutated version of the mouse
RIac cDNA (Boshart e al., 1991). As control, FTO2B cells were also treated
with 25 AM ZnC12. In vivo methylation of cells, purification and piperidine
cleavage of genomic DNA were carried out as described (Becker et al.,
1992). DMS-treated DNAs were subjected to a linear amplification reaction
using Taq polymerase followed by gel electrophoresis, transfer onto a nylon
membrane and hybridization as outlined in Reik et al. (1991) with
modifications. Briefly, the amplification reaction (in 100 y1) contained: 15
Ag DNA, 30 ng of a 27mer primer corresponding to the TAT sequence
-3457 to -3430 or to the PEPCK sequence -380 to -354, 500 AM of
each dNTP, 40 mM NaCl, 10 mM Tris-HCl (pH 8.9), 5 mM MgCl2,
0.17 mg/ml BSA and 5 U Taq polymerase (Perkin Elmer). Twenty five
cycles at 94°C for 1 min, 64°C for 1 min and 72°C for 1.6 min were
performed. The amplified DNA was further processed and analysed on
sequencing gels as described (Reik et al., 1991; Becker et al., 1992).
Genomic filters were hybridized at 68°C with a cDNA probe of high specific
activity synthesized from an RNA template (Weih et al., 1988). The probe
used for the TAT filter (HS127) recognized positions -3643 (HhaI) to
-3516 (StyI); the probe used for the PEPCK filter (NS158) recognized
positions -363 (NdeI) to -205 (StuI).
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